# OnCo record mabquest (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/mabquest/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "mabquest" ;
  schema:name "MabQuest"@en ;
  schema:alternateName "MabQuest SA"@en, "MabQuest Therapeutics"@en ;
  schema:description "MabQuest is a Swiss company developing a new kind of anti-PD-1 antibody, a checkpoint inhibitor that releases a brake on the immune system, which binds PD-1 at a different site from current drugs. It is in an early trial in advanced solid tumours."@en ;
  schema:url <https://onco.cc/companies/mabquest/>, <https://mabquest.co/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://mabquest.co/>, <https://mabquest.co/about-us>, <https://clinicaltrials.gov/study/NCT06514651> ;
  schema:addressCountry "CH" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/pd1/> .